Regulatory approvals from FDA and EUA and growing investment and policy support from governments worldwide forecast a bright outlook for the biotech industry in the long run.

Over the past month (from the first Friday in July) the Twitter Top 10 portfolio held up relatively well. It was only down about 1.5% while the S&P 500 index fell about 3%.